MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing
Fig 6
Activity of MK-8527 against HIV-1 subtypes.
Antiviral activity of MK-8527 was evaluated across 11 HIV-1 subtypes with the PhenoSense assay using vectors encoding protease and RT sequences derived from HIV-1 in human plasma for WT subtypes A (n = 3), A1 (n = 5), AE (n = 5), AG (n = 6), B (n = 5), BF (n = 5), C (n = 5), D (n = 4), F1 (n = 5), and G (n = 2). Geometric mean fold change from CNDO control is shown; error bars denote standard deviation. The underlying data for Fig 6 can be found in the S1 Data. RT, reverse transcriptase; WT, wild-type.